Trial Profile
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 09 Nov 2023 Planned End Date changed from 31 Dec 2030 to 31 Dec 2026.
- 15 Apr 2022 Planned primary completion date changed from 31 Dec 2027 to 18 Jul 2022.
- 13 Mar 2021 Status changed from recruiting to active, no longer recruiting.